Loading…

Celiac Disease and Celiac Antibodies in DM1 Patients: When Are Screening and Biopsy Recommended?

Introduction The prevalence of celiac disease (CD) is increased in diabetes mellitus type 1 (DM1) patients. In most cases, CD is diagnosed in asymptomatic patients and hence periodic screening tests are recommended, but the timing, frequency of tests and indication for duodenal biopsy is unclear. Th...

Full description

Saved in:
Bibliographic Details
Published in:Digestive diseases and sciences 2019-02, Vol.64 (2), p.487-492
Main Authors: Slae, Mordechai, Romem, Azi, Edri, Shalom, Toker, Ori, Wilschanski, Michael, Strich, David
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c438t-a9c381dd78053d2ca24bec618692767f60725103669e9d9d4f6222f23503a06a3
cites cdi_FETCH-LOGICAL-c438t-a9c381dd78053d2ca24bec618692767f60725103669e9d9d4f6222f23503a06a3
container_end_page 492
container_issue 2
container_start_page 487
container_title Digestive diseases and sciences
container_volume 64
creator Slae, Mordechai
Romem, Azi
Edri, Shalom
Toker, Ori
Wilschanski, Michael
Strich, David
description Introduction The prevalence of celiac disease (CD) is increased in diabetes mellitus type 1 (DM1) patients. In most cases, CD is diagnosed in asymptomatic patients and hence periodic screening tests are recommended, but the timing, frequency of tests and indication for duodenal biopsy is unclear. The purpose of this study was to investigate the dynamics of CD serology in DM1 and identify risk factors for CD. Methods Celiac serology and duodenal biopsy results from 1990 until 2015 were collected from patients with DM1. The outcome of positive celiac serology, the incidence and risk factors for CD in DM1 patients were investigated. Results A total of 314 DM1 patients who had celiac serology were identified, with follow-up period up to 23 years. Of 31 patients (9.9%) with positive celiac serology, 11(35.4%) had spontaneous normalization after various time periods. Eighteen patients were diagnosed with CD (58.1% of positive celiac serology, 5.73% of the study cohort). Age under 4.5 years was a risk factor for CD, but not family background of autoimmune diseases or gender. All patients with CD diagnosis were diagnosed during the first 6 years following DM1 diagnosis. Conclusion Screening asymptomatic DM1 patients for CD beyond 6 years after diagnosis is not recommended. Spontaneous normalization of CD serology occurs, and hence, serologic follow-up may be performed. In children with DM1 diagnosis under the age of 4.5 years or with positive CD serology at DM1 diagnosis, there is an increased risk for CD and therefore positive serology should lead to biopsy.
doi_str_mv 10.1007/s10620-018-5353-4
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2127660610</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712937246</galeid><sourcerecordid>A712937246</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-a9c381dd78053d2ca24bec618692767f60725103669e9d9d4f6222f23503a06a3</originalsourceid><addsrcrecordid>eNp1kUuPFCEUhYnROD2tP8CNIbpxU-MFqqDKzaTt8ZWM0fiIS6ThVsukClqoXsy_H9pqNRoNC8jlOyfn5hDygMEZA1BPMwPJoQLWVo1oRFXfIgvWKFHxRra3yQKYLG_G5Ak5zfkKADrF5F1yIkAo1bZyQb6ucfDG0guf0WSkJjh6HK3C5DfReczUB3rxltH3ZvIYpvyMfvmGga4S0o82IQYftj-Uz33c5Wv6AW0cRwwO3fk9cqc3Q8b7x3tJPr988Wn9urp89-rNenVZ2Vq0U2U6K1rmnGqhEY5bw-sNWsla2XElVS9B8YaBkLLDznWu7iXnvOeiAWFAGrEkT2bfXYrf95gnPfpscRhMwLjPmrPiI0EWjyV59Bd6FfcplHSFqgXnDa8L9HiGtmZA7UMfp2TswVOvFOOdULyWhTr7B1WOw9HbGLD3Zf6HgM0Cm2LOCXu9S3406Voz0IdS9VyqLqXqQ6n6EOXhMe9-M6L7pfjZYgH4DOTyFbaYfi_0f9cbVyOnQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214322524</pqid></control><display><type>article</type><title>Celiac Disease and Celiac Antibodies in DM1 Patients: When Are Screening and Biopsy Recommended?</title><source>Springer Nature</source><creator>Slae, Mordechai ; Romem, Azi ; Edri, Shalom ; Toker, Ori ; Wilschanski, Michael ; Strich, David</creator><creatorcontrib>Slae, Mordechai ; Romem, Azi ; Edri, Shalom ; Toker, Ori ; Wilschanski, Michael ; Strich, David</creatorcontrib><description>Introduction The prevalence of celiac disease (CD) is increased in diabetes mellitus type 1 (DM1) patients. In most cases, CD is diagnosed in asymptomatic patients and hence periodic screening tests are recommended, but the timing, frequency of tests and indication for duodenal biopsy is unclear. The purpose of this study was to investigate the dynamics of CD serology in DM1 and identify risk factors for CD. Methods Celiac serology and duodenal biopsy results from 1990 until 2015 were collected from patients with DM1. The outcome of positive celiac serology, the incidence and risk factors for CD in DM1 patients were investigated. Results A total of 314 DM1 patients who had celiac serology were identified, with follow-up period up to 23 years. Of 31 patients (9.9%) with positive celiac serology, 11(35.4%) had spontaneous normalization after various time periods. Eighteen patients were diagnosed with CD (58.1% of positive celiac serology, 5.73% of the study cohort). Age under 4.5 years was a risk factor for CD, but not family background of autoimmune diseases or gender. All patients with CD diagnosis were diagnosed during the first 6 years following DM1 diagnosis. Conclusion Screening asymptomatic DM1 patients for CD beyond 6 years after diagnosis is not recommended. Spontaneous normalization of CD serology occurs, and hence, serologic follow-up may be performed. In children with DM1 diagnosis under the age of 4.5 years or with positive CD serology at DM1 diagnosis, there is an increased risk for CD and therefore positive serology should lead to biopsy.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/s10620-018-5353-4</identifier><identifier>PMID: 30377886</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adolescent ; Adult ; Age Factors ; Antibodies ; Autoantibodies - immunology ; Biochemistry ; Biopsy ; Celiac disease ; Celiac Disease - diagnosis ; Celiac Disease - epidemiology ; Celiac Disease - immunology ; Celiac Disease - pathology ; Child ; Child, Preschool ; Cohort Studies ; Diabetes ; Diabetes Mellitus, Type 1 - epidemiology ; Duodenum - pathology ; Female ; Gastroenterology ; Gliadin - immunology ; GTP-Binding Proteins - immunology ; Health risk assessment ; Hepatology ; Humans ; Infant ; Male ; Mass Screening ; Medical research ; Medical screening ; Medicine ; Medicine &amp; Public Health ; Medicine, Experimental ; Oncology ; Original Article ; Reticulin - immunology ; Retrospective Studies ; Serologic Tests ; Transglutaminases - immunology ; Transplant Surgery ; Viral antibodies ; Young Adult</subject><ispartof>Digestive diseases and sciences, 2019-02, Vol.64 (2), p.487-492</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><rights>COPYRIGHT 2019 Springer</rights><rights>Digestive Diseases and Sciences is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-a9c381dd78053d2ca24bec618692767f60725103669e9d9d4f6222f23503a06a3</citedby><cites>FETCH-LOGICAL-c438t-a9c381dd78053d2ca24bec618692767f60725103669e9d9d4f6222f23503a06a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30377886$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Slae, Mordechai</creatorcontrib><creatorcontrib>Romem, Azi</creatorcontrib><creatorcontrib>Edri, Shalom</creatorcontrib><creatorcontrib>Toker, Ori</creatorcontrib><creatorcontrib>Wilschanski, Michael</creatorcontrib><creatorcontrib>Strich, David</creatorcontrib><title>Celiac Disease and Celiac Antibodies in DM1 Patients: When Are Screening and Biopsy Recommended?</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><addtitle>Dig Dis Sci</addtitle><description>Introduction The prevalence of celiac disease (CD) is increased in diabetes mellitus type 1 (DM1) patients. In most cases, CD is diagnosed in asymptomatic patients and hence periodic screening tests are recommended, but the timing, frequency of tests and indication for duodenal biopsy is unclear. The purpose of this study was to investigate the dynamics of CD serology in DM1 and identify risk factors for CD. Methods Celiac serology and duodenal biopsy results from 1990 until 2015 were collected from patients with DM1. The outcome of positive celiac serology, the incidence and risk factors for CD in DM1 patients were investigated. Results A total of 314 DM1 patients who had celiac serology were identified, with follow-up period up to 23 years. Of 31 patients (9.9%) with positive celiac serology, 11(35.4%) had spontaneous normalization after various time periods. Eighteen patients were diagnosed with CD (58.1% of positive celiac serology, 5.73% of the study cohort). Age under 4.5 years was a risk factor for CD, but not family background of autoimmune diseases or gender. All patients with CD diagnosis were diagnosed during the first 6 years following DM1 diagnosis. Conclusion Screening asymptomatic DM1 patients for CD beyond 6 years after diagnosis is not recommended. Spontaneous normalization of CD serology occurs, and hence, serologic follow-up may be performed. In children with DM1 diagnosis under the age of 4.5 years or with positive CD serology at DM1 diagnosis, there is an increased risk for CD and therefore positive serology should lead to biopsy.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Antibodies</subject><subject>Autoantibodies - immunology</subject><subject>Biochemistry</subject><subject>Biopsy</subject><subject>Celiac disease</subject><subject>Celiac Disease - diagnosis</subject><subject>Celiac Disease - epidemiology</subject><subject>Celiac Disease - immunology</subject><subject>Celiac Disease - pathology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cohort Studies</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 1 - epidemiology</subject><subject>Duodenum - pathology</subject><subject>Female</subject><subject>Gastroenterology</subject><subject>Gliadin - immunology</subject><subject>GTP-Binding Proteins - immunology</subject><subject>Health risk assessment</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Mass Screening</subject><subject>Medical research</subject><subject>Medical screening</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Medicine, Experimental</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Reticulin - immunology</subject><subject>Retrospective Studies</subject><subject>Serologic Tests</subject><subject>Transglutaminases - immunology</subject><subject>Transplant Surgery</subject><subject>Viral antibodies</subject><subject>Young Adult</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kUuPFCEUhYnROD2tP8CNIbpxU-MFqqDKzaTt8ZWM0fiIS6ThVsukClqoXsy_H9pqNRoNC8jlOyfn5hDygMEZA1BPMwPJoQLWVo1oRFXfIgvWKFHxRra3yQKYLG_G5Ak5zfkKADrF5F1yIkAo1bZyQb6ucfDG0guf0WSkJjh6HK3C5DfReczUB3rxltH3ZvIYpvyMfvmGga4S0o82IQYftj-Uz33c5Wv6AW0cRwwO3fk9cqc3Q8b7x3tJPr988Wn9urp89-rNenVZ2Vq0U2U6K1rmnGqhEY5bw-sNWsla2XElVS9B8YaBkLLDznWu7iXnvOeiAWFAGrEkT2bfXYrf95gnPfpscRhMwLjPmrPiI0EWjyV59Bd6FfcplHSFqgXnDa8L9HiGtmZA7UMfp2TswVOvFOOdULyWhTr7B1WOw9HbGLD3Zf6HgM0Cm2LOCXu9S3406Voz0IdS9VyqLqXqQ6n6EOXhMe9-M6L7pfjZYgH4DOTyFbaYfi_0f9cbVyOnQA</recordid><startdate>20190215</startdate><enddate>20190215</enddate><creator>Slae, Mordechai</creator><creator>Romem, Azi</creator><creator>Edri, Shalom</creator><creator>Toker, Ori</creator><creator>Wilschanski, Michael</creator><creator>Strich, David</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190215</creationdate><title>Celiac Disease and Celiac Antibodies in DM1 Patients: When Are Screening and Biopsy Recommended?</title><author>Slae, Mordechai ; Romem, Azi ; Edri, Shalom ; Toker, Ori ; Wilschanski, Michael ; Strich, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-a9c381dd78053d2ca24bec618692767f60725103669e9d9d4f6222f23503a06a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Antibodies</topic><topic>Autoantibodies - immunology</topic><topic>Biochemistry</topic><topic>Biopsy</topic><topic>Celiac disease</topic><topic>Celiac Disease - diagnosis</topic><topic>Celiac Disease - epidemiology</topic><topic>Celiac Disease - immunology</topic><topic>Celiac Disease - pathology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cohort Studies</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 1 - epidemiology</topic><topic>Duodenum - pathology</topic><topic>Female</topic><topic>Gastroenterology</topic><topic>Gliadin - immunology</topic><topic>GTP-Binding Proteins - immunology</topic><topic>Health risk assessment</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Mass Screening</topic><topic>Medical research</topic><topic>Medical screening</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Medicine, Experimental</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Reticulin - immunology</topic><topic>Retrospective Studies</topic><topic>Serologic Tests</topic><topic>Transglutaminases - immunology</topic><topic>Transplant Surgery</topic><topic>Viral antibodies</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Slae, Mordechai</creatorcontrib><creatorcontrib>Romem, Azi</creatorcontrib><creatorcontrib>Edri, Shalom</creatorcontrib><creatorcontrib>Toker, Ori</creatorcontrib><creatorcontrib>Wilschanski, Michael</creatorcontrib><creatorcontrib>Strich, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Slae, Mordechai</au><au>Romem, Azi</au><au>Edri, Shalom</au><au>Toker, Ori</au><au>Wilschanski, Michael</au><au>Strich, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Celiac Disease and Celiac Antibodies in DM1 Patients: When Are Screening and Biopsy Recommended?</atitle><jtitle>Digestive diseases and sciences</jtitle><stitle>Dig Dis Sci</stitle><addtitle>Dig Dis Sci</addtitle><date>2019-02-15</date><risdate>2019</risdate><volume>64</volume><issue>2</issue><spage>487</spage><epage>492</epage><pages>487-492</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><abstract>Introduction The prevalence of celiac disease (CD) is increased in diabetes mellitus type 1 (DM1) patients. In most cases, CD is diagnosed in asymptomatic patients and hence periodic screening tests are recommended, but the timing, frequency of tests and indication for duodenal biopsy is unclear. The purpose of this study was to investigate the dynamics of CD serology in DM1 and identify risk factors for CD. Methods Celiac serology and duodenal biopsy results from 1990 until 2015 were collected from patients with DM1. The outcome of positive celiac serology, the incidence and risk factors for CD in DM1 patients were investigated. Results A total of 314 DM1 patients who had celiac serology were identified, with follow-up period up to 23 years. Of 31 patients (9.9%) with positive celiac serology, 11(35.4%) had spontaneous normalization after various time periods. Eighteen patients were diagnosed with CD (58.1% of positive celiac serology, 5.73% of the study cohort). Age under 4.5 years was a risk factor for CD, but not family background of autoimmune diseases or gender. All patients with CD diagnosis were diagnosed during the first 6 years following DM1 diagnosis. Conclusion Screening asymptomatic DM1 patients for CD beyond 6 years after diagnosis is not recommended. Spontaneous normalization of CD serology occurs, and hence, serologic follow-up may be performed. In children with DM1 diagnosis under the age of 4.5 years or with positive CD serology at DM1 diagnosis, there is an increased risk for CD and therefore positive serology should lead to biopsy.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>30377886</pmid><doi>10.1007/s10620-018-5353-4</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0163-2116
ispartof Digestive diseases and sciences, 2019-02, Vol.64 (2), p.487-492
issn 0163-2116
1573-2568
language eng
recordid cdi_proquest_miscellaneous_2127660610
source Springer Nature
subjects Adolescent
Adult
Age Factors
Antibodies
Autoantibodies - immunology
Biochemistry
Biopsy
Celiac disease
Celiac Disease - diagnosis
Celiac Disease - epidemiology
Celiac Disease - immunology
Celiac Disease - pathology
Child
Child, Preschool
Cohort Studies
Diabetes
Diabetes Mellitus, Type 1 - epidemiology
Duodenum - pathology
Female
Gastroenterology
Gliadin - immunology
GTP-Binding Proteins - immunology
Health risk assessment
Hepatology
Humans
Infant
Male
Mass Screening
Medical research
Medical screening
Medicine
Medicine & Public Health
Medicine, Experimental
Oncology
Original Article
Reticulin - immunology
Retrospective Studies
Serologic Tests
Transglutaminases - immunology
Transplant Surgery
Viral antibodies
Young Adult
title Celiac Disease and Celiac Antibodies in DM1 Patients: When Are Screening and Biopsy Recommended?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T01%3A49%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Celiac%20Disease%20and%20Celiac%20Antibodies%20in%20DM1%20Patients:%20When%20Are%20Screening%20and%20Biopsy%20Recommended?&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=Slae,%20Mordechai&rft.date=2019-02-15&rft.volume=64&rft.issue=2&rft.spage=487&rft.epage=492&rft.pages=487-492&rft.issn=0163-2116&rft.eissn=1573-2568&rft_id=info:doi/10.1007/s10620-018-5353-4&rft_dat=%3Cgale_proqu%3EA712937246%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c438t-a9c381dd78053d2ca24bec618692767f60725103669e9d9d4f6222f23503a06a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=214322524&rft_id=info:pmid/30377886&rft_galeid=A712937246&rfr_iscdi=true